RXII - RXi Pharmaceuticals Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

RXi Pharmaceuticals Corporation

257 Simarano Drive
Suite 101
Marlborough, MA 01752
United States

Full Time Employees15

Key Executives

Dr. Geert Cauwenbergh Ph.D., Dr., Med.Sc.Pres, CEO, Acting CFO & Director611.95kN/A64
Ms. Caitlin KontulisDirector of Fin., Principal Accounting Officer, Sec. & ControllerN/AN/A32
Dr. Karen Bulock Ph.D.VP of ResearchN/AN/AN/A
Dr. Gerrit Dispersyn Dr. Med. ScChief Devel. OfficerN/AN/A43
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


RXi Pharmaceuticals Corporation, a clinical-stage company, focuses on developing therapeutics for unmet medical needs. It develops therapies based on its self-delivering RNAi (sd-rxRNA) platform; and Samcyprone topical immunomodulatory. The company??s clinical development programs include RXI-109, an sd-rxRNA compound, which is in Phase II clinical trial for preventing or reducing dermal scarring following scar revision surgery of an existing hypertrophic scar; and in Phase I/II clinical trial for treating retinal scarring, as well as in discovery stage for the treatment of corneal scarring. Its clinical development programs also comprise RXI-231, an sd-rxRNA compound targeting tyrosinase, which is in development stage as a cosmetic ingredient for treating uneven skin tone and pigmentation; and RXI-185, an sd-rxRNA compound targeting collagenase that is in development stage as a cosmetic ingredient for treating wrinkles and skin laxity. The company is also developing Samcyprone, a formulation of the small molecule diphenylcyclopropenone, which is in Phase IIa clinical trial for the clearance of common warts. In addition, it is developing cell-based cancer immunotherapies. RXi Pharmaceuticals Corporation has collaborative research agreements with Gustave Roussy to evaluate the potential of the company??s sd-rxRNA technology platform for use in cancer treatments; and Medigene AG to explore potential synergies of using RNAi technology in combination with Medigene's recombinant TCRs to develop modified T cells. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Corporate Governance

RXi Pharmaceuticals Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.